跳转至内容
Merck

268569

Sigma-Aldrich

三甲基铝 溶液

2.0 M in hexanes

别名:

Trimethylalane

登录查看公司和协议定价


About This Item

线性分子式:
(CH3)3Al
CAS号:
分子量:
72.09
Beilstein:
3587197
MDL號碼:
分類程式碼代碼:
12352103
PubChem物質ID:
NACRES:
NA.22

形狀

liquid

品質等級

濃度

2.0 M in hexanes

密度

0.683 g/mL at 25 °C

SMILES 字串

C[Al](C)C

InChI

1S/3CH3.Al/h3*1H3;

InChI 密鑰

JLTRXTDYQLMHGR-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

Trimethylaluminum is a Lewis acid having wide applications in organic synthesis. It is employed in organic reactions like cross-coupling reaction, methylenation, carboalumination, cyclopropanation, and rearrangement reactions. Tebbe Reagent (methylenation agent) can be prepared in situ by reacting trimethylaluminum with dichlorobis(cyclopentadienyl)titanium.

應用

与 4-溴-2,6-二叔丁基苯酚(货号394378)一起用于通过环氧化物的选择性重排制备各种羰基化合物。

訊號詞

Danger

危險分類

Aquatic Chronic 2 - Asp. Tox. 1 - Eye Dam. 1 - Flam. Liq. 2 - Pyr. Liq. 1 - Repr. 2 - Skin Corr. 1B - STOT SE 3 - Water-react 1

標靶器官

Central nervous system

安全危害

儲存類別代碼

4.2 - Pyrophoric and self-heating hazardous materials

水污染物質分類(WGK)

WGK 3

閃點(°F)

-0.4 °F - closed cup

閃點(°C)

-18 °C - closed cup


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Tetrahedron, 47, 6983-6983 (1991)
Tetrahedron Letters, 30, 5607-5607 (1989)
Mahtab Farzin et al.
Pathology, 47(4), 302-307 (2015-05-06)
BRCA1-associated protein 1 (BAP1) is a tumour suppressor gene frequently inactivated in mesothelioma, rarely also in association with germline mutation. BAP1 mutations have been associated with improved prognosis and distinct clinicopathological features. We sought to determine the clinicopathological significance of
Alexander C Kozen et al.
ACS nano, 9(6), 5884-5892 (2015-05-15)
Lithium metal is considered to be the most promising anode for next-generation batteries due to its high energy density of 3840 mAh g(-1). However, the extreme reactivity of the Li surface can induce parasitic reactions with solvents, contamination, and shuttled
J L L Robinson et al.
Oncogene, 33(50), 5666-5674 (2013-12-03)
Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with new generation second-line hormonal therapies affording limited improvement in disease outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the determinants of its transcriptional

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门